Status:
COMPLETED
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Secondary Progressive Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Documented diagnosis of SPMS, with or without relapses.
- Treatment with siponimod for at least 6 months.
- Exclusion criteria:
- None.
Exclusion
Key Trial Info
Start Date :
April 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 26 2024
Estimated Enrollment :
606 Patients enrolled
Trial Details
Trial ID
NCT07168694
Start Date
April 16 2024
End Date
September 26 2024
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936